In animal studies, BPC 157 is linked to protecting the blood vessels in the gut lining from damage caused by NSAIDs, which may help prevent the overlying tissue from breaking down.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether BPC 157 administration consistently reduces markers of gastrointestinal endothelial injury (e.g., plasma von Willebrand factor, soluble thrombomodulin) in humans taking NSAIDs.
A systematic review and meta-analysis of all published randomized controlled trials in adults taking NSAIDs for ≥4 weeks, measuring plasma biomarkers of endothelial injury (von Willebrand factor, soluble thrombomodulin, endothelin-1) pre- and post-treatment, comparing BPC 157 (10 µg/kg/day) to placebo.
An RCT would determine whether BPC 157 causally reduces NSAID-induced endothelial injury in humans, measured by circulating biomarkers.
A double-blind, placebo-controlled trial of 80 healthy adults taking daily naproxen 500 mg for 14 days, randomized to receive oral BPC 157 (10 µg/kg twice daily) or placebo, with primary outcome: change in plasma von Willebrand factor and soluble thrombomodulin levels from baseline to day 14.
A prospective cohort would determine whether individuals taking BPC 157 alongside NSAIDs show slower progression of endothelial dysfunction over time.
A prospective cohort study following 300 patients with chronic pain on NSAIDs, measuring plasma endothelial injury biomarkers and microvascular function (via flow-mediated dilation) at baseline, 6, and 12 months, stratified by BPC 157 use (yes/no, dose, duration).
A case-control study would assess whether patients with NSAID-induced GI bleeding have higher baseline endothelial injury markers than those without bleeding, and whether BPC 157 use is associated with lower levels.
A case-control study comparing 75 patients with NSAID-induced GI bleeding to 150 matched controls without bleeding, measuring plasma endothelial injury biomarkers and retrospectively assessing prior BPC 157 use, adjusting for NSAID dose and comorbidities.
A cross-sectional study would identify whether individuals currently using BPC 157 have lower endothelial injury biomarkers than non-users at a single time point.
A cross-sectional analysis of 150 adults on chronic NSAIDs, measuring plasma von Willebrand factor and soluble thrombomodulin levels and comparing between those currently using BPC 157 (≥30 days) and those not using it, adjusting for age, NSAID type, and duration.